Aims and Scope

The Kidney Cancer Journal (KCJ) is an international, peer-reviewed, open access journal on kidney cancers.

The objective of KCJ is to serve as the most comprehensive, peer-reviewed and free-access information that address key frontline research topics and cutting-edge advances in the rapidly changing field of kidney/renal cancers.

Over the last 20 years, KCJ accomplishes its objective by publishing original and timely review articles (basic, translational, and clinical studies) that facilitate the transfer of knowledge from the laboratory to the bedside; contribute to cancer prevention, early detection, diagnosis, cure, and rehabilitation of kidney cancer. KCJ seeks to impart highly relevant and timely information to a broad audience of kidney cancer and related specialists in the field.

Also, KCJ provides a unique platform for roundtable discussion, commentaries and breakthroughs that are valuable for clinicians, scientists, and policy makers, as well as patients & advocates in the kidney cancer space. The latest opportunities, challenges and potential impact of basic, translational and clinical findings, industry R&D, technology and innovation, ethics, or cancer policy and funding are equally presented and debated in an authoritative but reader-friendly format.

KCJ publishes original articles, reviews, commentary articles, clinical case studies as well as letters to the editor. Also, KCJ offers special issues and supplements that provide coverages for key conferences such as ASCO meeting and highlights from the annual International Kidney Cancer Association Meetings.

KCJ is distributed as a complimentary professional service to approximately 12,300 physicians, including all medical oncologists and targeted urologists. KCJ utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 oncologists/physicians who are leading investigators in this field.